Ambit Biosciences (AMBI +1.3%) moves up on a number of upbeat initiations by the Street as it comes out of its quiet period. Baird, BMO and Leerink all start the shares with an Outperform, while Citigroup initiates coverage with a Buy. Notably, Leerink's Howard Liang says that it sees AMBI's quizartinib as the best-in-class FLT3 inhibitor, which currently represents the mainstay for targeted therapy for acute myeloid leukemia.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs